Literature DB >> 25034395

Role of surgery in multi-modality treatment for carcinomatous pleuritis in patients with non-small cell lung cancer.

Tetsuhiko Go1, Noriyuki Misaki, Natsumi Matsuura, Sung Soo Chang, Shintarou Tarumi, Hiroyasu Yokomise.   

Abstract

OBJECTIVE: To evaluate the role of surgery in the treatment of the patients with non-small cell lung cancer with pleural dissemination.
METHODS: The clinical records of 25 patients (mean age 69 years) diagnosed with carcinomatous pleuritis during a thoracotomy by pathological examination and followed by surgery between 1994 and 2012 were reviewed. The treatment modality, including surgery, the clinicopathologic characteristics and 5-year survival were analyzed.
RESULTS: There were 16 adenocarcinomas, 6 squamous cell carcinomas and 3 large cell carcinomas. Surgery included resection of the main tumor by partial resection in 10 cases, segmentectomy in 2 cases, lobar resection in 12 cases and bilobectomy in 1 case. Intrathoracic irrigation was performed in 20 cases. The pathological N status was N0/N1/N2/Nx: 10/6/7/2. Fifteen patients received adjuvant therapy. The overall 5-year survival rate was 22.2 %. The 5-year survival rates of the N0, N1 and N2 groups were 36.0, 16.7 and 14.3 %, respectively (p = 0.0068). Nine patients lived more than 3 years including 5 in N0, 3 in N1 and 1 in N2.
CONCLUSIONS: Surgery should not be excluded from the multi-modality treatment of patients with carcinomatous pleuritis because there are some patients who could benefit from surgery especially if they are in N0 status.

Entities:  

Mesh:

Year:  2014        PMID: 25034395     DOI: 10.1007/s00595-014-0987-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  21 in total

1.  Lung cancer with pleural dissemination: why not operation?

Authors:  Marc Riquet; Christophe Foucault; François Souilamas
Journal:  Ann Thorac Surg       Date:  2002-11       Impact factor: 4.330

2.  Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor.

Authors:  D Manac'h; M Riquet; J Medioni; F Le Pimpec-Barthes; A Dujon; C Danel
Journal:  Ann Thorac Surg       Date:  2001-04       Impact factor: 4.330

3.  The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer.

Authors:  J Buhr; K H Berghäuser; S Gonner; C Kelm; E A Burkhardt; W M Padberg
Journal:  J Thorac Cardiovasc Surg       Date:  1997-04       Impact factor: 5.209

4.  Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Authors:  Yelena Y Janjigian; Bernard J Park; Maureen F Zakowski; Marc Ladanyi; William Pao; Sandra P D'Angelo; Mark G Kris; Ronglai Shen; Junting Zheng; Christopher G Azzoli
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

5.  Retrospective review of lung cancer patients with pleural dissemination after limited operations combined with parietal pleurectomy.

Authors:  Yasuhiko Ohta; Yosuke Shimizu; Isao Matsumoto; Masaya Tamura; Makoto Oda; Go Watanabe
Journal:  J Surg Oncol       Date:  2005-09-15       Impact factor: 3.454

6.  Prognosis of resected non-small cell lung cancer patients with carcinomatous pleuritis of minimal disease.

Authors:  Y Ichinose; R Tsuchiya; T Koike; O Kuwahara; K Nakagawa; Y Yamato; K Kobayashi; Y Watanabe; M Kase; K Yokoi
Journal:  Lung Cancer       Date:  2001-04       Impact factor: 5.705

7.  The impact on survival of positive intraoperative pleural lavage cytology in patients with non-small-cell lung cancer.

Authors:  Keiju Aokage; Junji Yoshida; Genichiro Ishii; Sotarou Enatsu; Tomoyuki Hishida; Mitsuyo Nishimura; Yutaka Nishiwaki; Kanji Nagai
Journal:  J Thorac Cardiovasc Surg       Date:  2009-09-17       Impact factor: 5.209

8.  Treatment of malignant pleural effusion.

Authors:  K Reshad; K Inui; Y Takeuchi; Y Takahashi; S Hitomi
Journal:  Chest       Date:  1985-09       Impact factor: 9.410

Review 9.  The revised TNM staging system for lung cancer.

Authors:  Ramon Rami-Porta; John J Crowley; Peter Goldstraw
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 1.520

10.  Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer.

Authors:  H Kondo; H Asamura; K Suemasu; T Goya; R Tsuchiya; T Naruke; K Yamagishi; Y Uei
Journal:  J Thorac Cardiovasc Surg       Date:  1993-12       Impact factor: 5.209

View more
  9 in total

1.  Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS.

Authors:  Runlei Hu; Hong Jiang; Hu Li; Dongshan Wei; Guoqing Wang; Shenglin Ma
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Should primary tumor be resected for non-small cell lung cancer with malignant pleural disease unexpectedly found during operation?-a systemic review and meta-analysis.

Authors:  Yuyang Xu; Nan Chen; Zihuai Wang; Yingyi Zhang; Jiandong Mei; Chengwu Liu; Lunxu Liu
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Predictive factors related to pleural dissemination in non-small cell lung cancer.

Authors:  Nozomu Motono; Shun Iwai; Iijima Yoshihito; Katsuo Usuda; Sohsuke Yamada; Hidetaka Uramoto
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

4.  The Role of Primary Tumor Resection in Patients with Pleural Metastasis Encountered at the Time of Surgery.

Authors:  Samina Park; Yongwoo Chung; Hyun Joo Lee; In Kyu Park; Chang Hyun Kang; Young Tae Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2020-06-05

5.  Primary tumor resection of non-small cell lung cancer patients with ipsilateral pleural dissemination (M1a) in the era of targeted therapy.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Fan Yang
Journal:  Thorac Cancer       Date:  2020-09-18       Impact factor: 3.500

6.  Surgical Resection of Primary Tumors Provides Survival Benefits for Lung Cancer Patients With Unexpected Pleural Dissemination.

Authors:  Liwen Fan; Haitang Yang; Ke Han; Yang Zhao; Wen Gao; Ralph A Schmid; Feng Yao; Heng Zhao
Journal:  Front Surg       Date:  2021-06-23

Review 7.  New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Zhenfan Wang; Xianping Liu; Fan Yang
Journal:  Ann Transl Med       Date:  2021-06

8.  [Observation - An Favorable Option Forthoracic Dissemination Patients with Lung Adenocarcinoma or Squamous Carcinoma].

Authors:  Ying Chen; Wei Li; Wenfang Tang; Xuening Yang; Wenzhao Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-04-20

9.  Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non-Small Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination.

Authors:  Zhenfan Wang; Hao Li; Taorui Liu; Zewen Sun; Fan Yang; Guanchao Jiang
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.